194 related articles for article (PubMed ID: 15272579)
1. [Biomarkers in breast cancer].
Kurebayashi J
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1021-6. PubMed ID: 15272579
[TBL] [Abstract][Full Text] [Related]
2. [Biomarkers, tumor markers and prognostic markers in breast cancer].
Kurebayashi J
Nihon Rinsho; 2006 Mar; 64(3):461-6. PubMed ID: 16529036
[TBL] [Abstract][Full Text] [Related]
3. [Tumor markers in breast cancer].
Kurebayashi J
Gan To Kagaku Ryoho; 2004 Nov; 31(12):2077-81. PubMed ID: 15570944
[TBL] [Abstract][Full Text] [Related]
4. [Tumor markers in breast cancer].
Harada Y; Ohuchi N; Ishida T; Ohnuki K
Gan To Kagaku Ryoho; 2001 Jul; 28(7):1035-40. PubMed ID: 11478135
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer and neoadjuvant therapy: any predictive marker?
Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
[TBL] [Abstract][Full Text] [Related]
6. Serum tumor markers in patients with breast cancer.
Lumachi F; Basso SM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):921-31. PubMed ID: 15485325
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients.
Abendstein B; Daxenbichler G; Windbichler G; Zeimet AG; Geurts A; Sweep F; Marth C
Anticancer Res; 2000; 20(1B):569-72. PubMed ID: 10769727
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.
Molina R; Filella X; Alicarte J; Zanon G; Pahisa J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1035-41. PubMed ID: 12820344
[TBL] [Abstract][Full Text] [Related]
10. Detection of tumor markers including carcinoembryonic antigen, APC, and cyclin D2 in fine-needle aspiration fluid of breast.
Lee A; Kim Y; Han K; Kang CS; Jeon HM; Shim SI
Arch Pathol Lab Med; 2004 Nov; 128(11):1251-6. PubMed ID: 15508191
[TBL] [Abstract][Full Text] [Related]
11. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
12. Tumour marker measurements in the diagnosis and monitoring of breast cancer.
Cheung KL; Graves CR; Robertson JF
Cancer Treat Rev; 2000 Apr; 26(2):91-102. PubMed ID: 10772967
[TBL] [Abstract][Full Text] [Related]
13. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
[TBL] [Abstract][Full Text] [Related]
14. Biological markers in breast cancer prognosis and treatment.
Kesisis G; Kontovinis LF; Gennatas K; Kortsaris AH
J BUON; 2010; 15(3):447-54. PubMed ID: 20941809
[TBL] [Abstract][Full Text] [Related]
15. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
[TBL] [Abstract][Full Text] [Related]
16. Circulating hormone levels in breast cancer patients. correlation with serum tumor markers and the clinical and biological features of the tumors.
Hernández L; Nuñez-Villarl MJ; Martínez-Arribas F; Pollán M; Schneider J
Anticancer Res; 2005; 25(1B):451-4. PubMed ID: 15816610
[TBL] [Abstract][Full Text] [Related]
17. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery.
Nakamura T; Kimura T; Umehara Y; Suzuki K; Okamoto K; Okumura T; Morizumi S; Kawabata T
Surg Today; 2005; 35(1):19-21. PubMed ID: 15622458
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
19. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.
Dowsett M; Dunbier AK
Clin Cancer Res; 2008 Dec; 14(24):8019-26. PubMed ID: 19088018
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic and predictive factors in breast cancer].
Bozhok AA; Semiglazov VF; Semiglazov VV; Arzumanov AS; Klettsel' AE
Vopr Onkol; 2005; 51(4):434-43. PubMed ID: 16308974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
